We are live on ! Find out more
NHAS

Novo Holdings A/S Portfolio holdings

AUM $1.23B
1-Year Est. Return 81.32%
This Fund
S&P 500
This Quarter Est. Return
+5.32%
1 Year Est. Return
+81.32%
3 Year Est. Return
+192.63%
5 Year Est. Return
+125.03%
10 Year Est. Return
+943.65%
AUM
$1.6B
AUM Growth
-$496M
Cap. Flow
-$440M
Cap. Flow %
-27.44%
Top 10 Hldgs %
54.93%
Holding
55
New
3
Increased
15
Reduced
6
Closed
7

Top Buys

Rank Stock Value
1
IRON icon
Disc Medicine
IRON
+$117M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$17.4M
3
BLU
BELLUS Health Inc.
BLU
+$15.8M
4
DICE
DICE Therapeutics, Inc. Common Stock
DICE
+$15.2M
5
RLYB icon
Rallybio
RLYB
+$12.3M

Top Sells

Rank Stock Value
1
VTI icon
Vanguard Morningstar Total Stock Market ETF
VTI
+$501M
2
ACLX
Arcellx
ACLX
+$39.2M
3
BN icon
Brookfield
BN
+$20M
4
MIST icon
Milestone Pharmaceuticals
MIST
+$18.4M
5
BSX icon
Boston Scientific
BSX
+$17.7M

Sector Composition

Rank Sector Weight
1 Healthcare 69.58%
2 Technology 18.99%
3 Financials 4.49%
4 Communication Services 4.18%
5 Consumer Discretionary 2.75%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BPMC
26
DELISTED
Blueprint Medicines
BPMC
$16.2M 1.01%
370,000
+53,326
+17% +$2.56M
INSP icon
27
Inspire Medical Systems
INSP
$1.74B
$15.9M 1%
63,304
+2,404
+4% +$513K
NARI
28
DELISTED
Inari Medical, Inc. Common Stock
NARI
$15.3M 0.96%
240,800
+27,600
+13% +$2M
RLYB icon
29
Rallybio
RLYB
$85.8M
$15.1M 0.94%
287,001
+208,136
+264% +$12.3M
TMCI icon
30
Treace Medical Concepts
TMCI
$309M
$14.7M 0.91%
637,317
+49,009
+8% +$1.13M
SILK
31
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
$14.6M 0.91%
275,511
– –
DICE
32
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$14.5M 0.91%
+465,000
New +$15.2M
BLU
33
DELISTED
BELLUS Health Inc.
BLU
$14M 0.87%
+1,698,084
New +$15.8M
CRNX icon
34
Crinetics Pharmaceuticals
CRNX
$8.92B
$13.5M 0.84%
737,057
+105,430
+17% +$1.86M
PHVS icon
35
Pharvaris
PHVS
$2.44B
$13.4M 0.83%
1,187,307
+577,307
+95% +$3.04M
LVTX
36
DELISTED
LAVA Therapeutics
LVTX
$11.6M 0.73%
3,327,312
– –
ABCL icon
37
AbCellera Biologics
ABCL
$2.12B
$11.4M 0.71%
1,126,915
– –
KZR
38
DELISTED
Kezar Life Sciences
KZR
$8.27M 0.52%
117,500
+57,662
+96% +$4.28M
OKUR
39
OnKure Therapeutics
OKUR
$168M
$7.99M 0.5%
343,038
– –
IOBT
40
DELISTED
IO Biotech
IOBT
$7.54M 0.47%
3,277,932
– –
CYT
41
DELISTED
Cyteir Therapeutics, Inc. Common Stock
CYT
$6.5M 0.41%
3,940,413
– –
KNTE
42
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$4.98M 0.31%
815,707
– –
SPRB
43
Spruce Biosciences
SPRB
$129M
$4.95M 0.31%
60,191
– –
LUNG icon
44
Pulmonx
LUNG
$87.6M
$4.3M 0.27%
510,555
– –
GRTX
45
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
$3.66M 0.23%
2,459,021
– –
DMRA
46
Damora Therapeutics, Inc. Ordinary Shares
DMRA
$1.84B
$2.87M 0.18%
99,912
– –
MQ icon
47
Marqeta
MQ
$1.66B
$2.7M 0.17%
110,390
– –
SPRO icon
48
Spero Therapeutics
SPRO
$73M
$811K 0.05%
468,902
– –
ALGS icon
49
Aligos Therapeutics
ALGS
$34.9M
– –
-78,000
Closed -$2.15M
BOLT icon
50
Bolt Biotherapeutics
BOLT
$7.78M
– –
-185,200
Closed -$5.48M
1
2
3

Similar funds

MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
HTHT
Hemenway Trust Hemenway Trust Salem, New Hampshire $1.24B AUM 16.52% 1-Year Est. Return
BCP
BlackBarn Capital Partners New York $1.24B AUM 55.98% 1-Year Est. Return
SPC
Stony Point Capital New York $1.24B AUM 32.69% 1-Year Est. Return
SC
Strategy Capital Los Altos, California $1.22B AUM 27.02% 1-Year Est. Return

Novo Holdings A/S's Q4 2022 Portfolio in Review

As of Q4 2022, Novo Holdings A/S held 55 positions worth $1.6B, down 24% from $2.1B the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Novo Holdings A/S withdrew a net $440M in Q4 2022, closing 7 positions and reducing 6 holdings. Its most notable exit was Vanguard Morningstar Total Stock Market ETF, an estimated $501M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 70% of assets, up from 52% a quarter earlier, followed by Technology and Financials.

Against the trend, Novo Holdings A/S opened a new position in Disc Medicine worth $46.6M.

  • Novo Holdings A/S's largest Q4 2022 buy was Disc Medicine: 2,340,772 shares worth $46.6M.
  • Novo Holdings A/S added most to Seagen Inc. Common Stock in Q4 2022, an estimated $17.4M increase.
  • Novo Holdings A/S's biggest Q4 2022 reduction was Arcellx, cutting an estimated $39.2M.
  • Novo Holdings A/S fully exited Vanguard Morningstar Total Stock Market ETF in Q4 2022, selling an estimated $501M.
  • Novo Holdings A/S's ten largest holdings make up 55% of its $1.6B portfolio in Q4 2022.
  • Novo Holdings A/S opened 3 new positions and closed 7 in Q4 2022.
  • Novo Holdings A/S's portfolio value fell 24% quarter-over-quarter to $1.6B.

Based on Novo Holdings A/S's 13F filing for Q4 2022, filed 14 Feb 2023.